Apr 15, 2008 - Znomics, Inc. (OTCBB:ZNOM), a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, announced today the launch of a program to find lead drug compounds for the treatment of obesity. Znomics obtained from Oregon Health & Science University (OHSU) an exclusive biological license to a genetic model of obesity using the zebrafish developed in the OHSU laboratory of Znomics' co-founder Roger Cone, Ph.D., a leading international researcher in the field of weight regulation. Under the direction of Stephane Berghmans, director of drug discovery at Znomics, the company intends to refine Dr. Cone's obesity model for use in the screening of small molecule compounds. The company aims to identify pre-clinical drug candidates for obesity and to partner with a pharmaceutical or biotechnology company to advance these candidates into human clinical studies... Znomics' Press Release -
